Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oral formulation of Aloxi approved in the US

This article was originally published in Scrip

Executive Summary

A new oral capsule formulation of Helsinn Healthcare/Eisai's 5HT3-antagonist Aloxi (palonosetron hydrochloride) has been approved by the US FDA for the prevention of nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A single 0.5mg capsule is administered around one hour before treatment. A 0.25mg iv formulation of the product has been available in the US since 2003 for the prevention of acute and delayed nausea and vomiting in the same setting and also for prevention of acute nausea and vomiting from initial and repeat courses of highly emetogenic chemotherapy. Eisai acquired North American rights as part of its January purchase of MGI Pharma, which had licensed these from Helsinn. A 0.075mg iv formulation was launched in the US in July for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts